Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 65Neoplasm Metastasis 6Prostatic Neoplasms, Castration-Resistant 5Non-metastatic Castration-resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 3Neoplasms 3Breast Neoplasms 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Hormone-sensitive Prostate Cancer 2Male Urogenital Diseases 2Genital Diseases, Male 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Adenocarcinoma 2Urogenital Diseases 1Thrombocytosis 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Non-Metastatic 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-metastatic Prostate Cancer 1Neoplasms by Site 1Myeloproliferative Disorders 1

Interventions

darolutamide 4enzalutamide 2apalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Non-metastatic Castration-resistant Prostate Cancer × darolutamide × Clear all
NCT07538843 2026-05-15

DARE

Bayer

Not yet recruiting
800 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06334120 2026-05-13

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Bayer

Recruiting
600 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT06013475 2025-06-12

DEAR-EXT

Bayer

Completed
1,375 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT05362149 2024-03-20

DEAR

Bayer

Completed
870 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡